OpenURL Connection Search

Select item for more details and to access through your institution.

Correction to: Merkel Cell Carcinoma Outcomes: Does AJCC8 Underestimate Survival?
Published in:
2020
By:
- Farley, C. R.;
- Perez, M. C.;
- Soelling, S. J.;
- Delman, K. A.;
- Harit, A.;
- Wuthrick, E. J.;
- Messina, J. L.;
- Sondak, V. K.;
- Zager, J. S.;
- Lowe, M. C.
Publication type:
Correction Notice
Merkel Cell Carcinoma Outcomes: Does AJCC8 Underestimate Survival?
Published in:
Annals of Surgical Oncology: An Oncology Journal for Surgeons, 2020, v. 27, n. 6, p. 1978, doi. 10.1245/s10434-019-08187-w
By:
- Farley, C. R.;
- Perez, M. C.;
- Soelling, S. J.;
- Delman, K. A.;
- Harit, A.;
- Wuthrick, E. J.;
- Messina, J. L.;
- Sondak, V. K.;
- Zager, J. S.;
- Lowe, M. C.
Publication type:
Article
Phase I/II trial for the treatment of cutaneous and subcutaneous tumors using electrochemotherapy.
Published in:
1996
By:
- Heller, Richard;
- Jaroszeski, Mark J.;
- Glass, L. Frank;
- Messina, Jane L.;
- Rapaport, David P.;
- DeConti, Ronald C.;
- Fenske, Neil A.;
- Gilbert, Richard A.;
- Mir, Lluis M.;
- Reintgen, Douglas S.;
- Heller, R;
- Jaroszeski, M J;
- Glass, L F;
- Messina, J L;
- Rapaport, D P;
- DeConti, R C;
- Fenske, N A;
- Gilbert, R A;
- Mir, L M;
- Reintgen, D S
Publication type:
journal article
Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma.
Published in:
British Journal of Cancer, 2012, v. 106, n. 1, p. 85, doi. 10.1038/bjc.2011.514
By:
- Algazi, A P;
- Weber, J S;
- Andrews, S C;
- Urbas, P;
- Munster, P N;
- DeConti, R C;
- Hwang, J;
- Sondak, V K;
- Messina, J L;
- McCalmont, T;
- Daud, A I
Publication type:
Article
Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.
Published in:
2010
By:
- Paraiso, K. H. T.;
- Fedorenko, I. V.;
- Cantini, L. P.;
- Munko, A. C.;
- Hall, M.;
- Sondak, V. K.;
- Messina, J. L.;
- Flaherty, K. T.;
- Smalley, K. S. M.
Publication type:
journal article

Found: 5

Correction to: Merkel Cell Carcinoma Outcomes: Does AJCC8 Underestimate Survival?

Merkel Cell Carcinoma Outcomes: Does AJCC8 Underestimate Survival?

Phase I/II trial for the treatment of cutaneous and subcutaneous tumors using electrochemotherapy.

Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma.

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.